Search Within

David Chung

Formats
  1. Meeting Abstract (177)
  2. Journal Article (63)
  3. Research Letter (4)
  4. Correspondence (2)
  5. Book Section (1)
  6. Review (1)
Groups
  1. Bone Marrow Transplant (248)
  2. Center for Hematologic Malignancies (248)
  3. Department of Medicine (248)
  4. Hematologic Malignancies, Division of (248)
  5. Survivorship Research (220)
  6. Myeloma (189)

More Groups

People
  1. Sergio Giralt (207)
  2. Heather Landau (206)
  3. Alexander Lesokhin (174)
  4. Hani Hassoun (165)
  5. Gunjan Shah (155)
  6. Neha Korde (139)

More People

Years
  1. 2025 (3)
  2. 2024 (40)
  3. 2023 (40)
  4. 2022 (34)
  5. 2021 (15)
  6. 2020 (18)

More Years

Publications
  1. Blood (98)
  2. Clinical Lymphoma, Myeloma and Leukemia (44)
  3. Biology of Blood and Marrow Transplantation (28)
  4. Leukemia and Lymphoma (9)
  5. Journal of Clinical Oncology (8)
  6. Transplantation and Cellular Therapy (7)

More Publications

Publishers
  1. American Society of Hematology (103)
  2. Elsevier Inc. (82)
  3. Nature Publishing Group (13)
  4. American Association for Cancer Research (9)
  5. Taylor & Francis Group (9)
  6. American Society of Clinical Oncology (8)

More Publishers

Results (248)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Phase I first-in-class trial of MCARH109, a G protein coupled receptor class C group 5 member D (GPRC5D) targeted CAR T cell therapy in patients with relapsed or refractory multiple myeloma
    Meeting Abstract

    Mailankody, S.; Diamonte, C.; Fitzgerald, L.; Kane, P.; Wang, X.; Sikder, D. S.; Senechal, B.; Bermudez, V. P.; Frias, D.; Morgan, J.; more...
    Blood (2021)

    Fulltext@MSK | Save
  • Belantamab mafodotin in patients with relapsed/refractory multiple myeloma, a real-world experience
    Meeting Abstract

    Hultcrantz, M.; Orozco, J.; Peterson, T. J.; Derkach, A.; Hassoun, H.; Korde, N.; Lu, S. X.; Mailankody, S.; Patel, D.; Shah, U. A.; more...
    Blood (2021)

    Fulltext@MSK | Save
  • Impact of autologous hematopoietic cell transplant (HCT) followed by dendritic cell/myeloma fusion vaccine with lenalidomide maintenance in increasing multiple myeloma (MM) immunity (BMT CTN 1401)
    Meeting Abstract

    Chung, D. J.; Shah, N.; Stroopinsky, D.; Wu, J.; Bisharat, L.; Callander, N. S.; Logan, B. R.; Anderson, K. C.; Chodon, T.; Mohan, M.; more...
    Blood (2021)

    Fulltext@MSK | Save
  • Daratumumab, carfilzomib, lenalidomide, & dexamethasone for relapsed/refractory myeloma with salvage autologous hematopoietic cell transplant: Interim analysis of the multicenter 2nd chance protocol
    Meeting Abstract

    Shah, G.; Bal, S.; Rodriguez, C.; Chhabra, S.; Bayer, R.; Costa, L.; Lambird, J.; Ferrer, C.; Parascondola, A.; Marcello, L.; more...
    Clinical Lymphoma, Myeloma and Leukemia (2021)

    Fulltext@MSK | Save
  • Sustained minimal residual disease negativity in multiple myeloma is impacted positively by stool butyrate and healthier plant forward diets
    Meeting Abstract

    Shah, U.; Derkach, A.; Adintori, P.; Cross, J.; Maclachlan, K.; Mailankody, S.; Korde, N.; Hultcrantz, M.; Hassoun, H.; Tan, C.; more...
    Clinical Lymphoma, Myeloma and Leukemia (2021)

    Fulltext@MSK | Save
  • Predictors of humoral response to SARS-CoV-2 vaccination after hematopoietic cell transplantation and CAR T-cell therapy
    Journal Article

    Tamari, R.; Politikos, I.; Knorr, D. A.; Vardhana, S. A.; Young, J. C.; Marcello, L. T.; Doddi, S.; Devlin, S. M.; Ramanathan, L. V.; Pessin, M. S.; more...
    Blood Cancer Discovery (2021)

    Fulltext@MSK | Save
  • Disease- and therapy-specific impact on humoral immune responses to COVID-19 vaccination in hematologic malignancies
    Journal Article

    Chung, D. J.; Shah, G. L.; Devlin, S. M.; Ramanathan, L. V.; Doddi, S.; Pessin, M. S.; Hoover, E.; Marcello, L. T.; Young, J. C.; Boutemine, S. R.; more...
    Blood Cancer Discovery (2021)

    Fulltext@MSK | Save
  • Safety and effectiveness of weekly carfilzomib, lenalidomide, dexamethasone, and daratumumab combination therapy for patients with newly diagnosed multiple myeloma the MANHATTAN nonrandomized clinical trial
    Journal Article

    Landgren, O.; Hultcrantz, M.; Diamond, B.; Lesokhin, A. M.; Mailankody, S.; Hassoun, H.; Tan, C.; Shah, U. A.; Lu, S. X.; Salcedo, M.; more...
    JAMA Oncology (2021)

    Fulltext@MSK | Save
  • Dynamics of minimal residual disease in patients with multiple myeloma on continuous lenalidomide maintenance: A single-arm, single-centre, phase 2 trial
    Journal Article

    Diamond, B.; Korde, N.; Lesokhin, A. M.; Smith, E. L.; Shah, U.; Mailankody, S.; Hultcrantz, M.; Hassoun, H.; Lu, S. X.; Tan, C.; more...
    The Lancet Haematology (2021)

    Fulltext@MSK | Save
  • Cellular therapy during COVID-19: Lessons learned and preparing for subsequent waves
    Journal Article

    Nawas, M. T.; Shah, G. L.; Feldman, D. R.; Ruiz, J. D.; Robilotti, E. V.; Aslam, A. A.; Dundas, M.; Kamboj, M.; Barker, J. N.; Cho, C.; more...
    Transplantation and Cellular Therapy (2021)

    Fulltext@MSK | Save